We are studying whether adding INBRX-106 to pembrolizumab helps patients with recurrent or metastatic head and neck cancer. This trial focuses on effectiveness, safety, and quality of life for those with high PD-L1 expression.
Health conditions and diseases that the clinical trial is designed to study and treat.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a type of cancer that originates in the squamous cells of the head and neck region, often linked to risk factors like tobacco use and HPV infection. It can lead to symptoms such as difficulty swallowing, persistent sore throat, and changes in voice.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
